Back to results
US 10,117,944 B2Granted
Targeted therapeutics
AssigneeMadrigal Pharmaceuticals, Inc.
InventorsDinesh U. Chimmanamada, Weiwen Ying
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeMadrigal Pharmaceuticals, Inc.
InventorsDinesh U. Chimmanamada, Weiwen Ying
Estimating the term…
The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
A binding moiety-drug conjugate (SDC-TRAP) comprising a binding moiety and an effector moiety, wherein the effector moiety is a proteasome inhibitor selected from the group consisting of bortezomib, ixazomib, and delanzomib, or fragment thereof, the binding moiety binds to HSP90, and the binding moiety and the effector moiety are covalently attached.
A binding moiety-drug conjugate (SDC-TRAP) or its pharmaceutically acceptable salt, wherein the SDC-TRAP is selected from the group consisting of SDC-TRAP-0236, SDC-TRAP-0237, SDC-TRAP-0238, SDC-TRAP-0239, SDC-TRAP-0240, SDC-TRAP-0241, SDC-TRAP-0242, SDC-TRAP-0243, SDC-TRAP-0244, SDC-TRAP-0245, SDC-TRAP-0246, SDC-TRAP-0247, SDC-TRAP-0248, SDC-TRAP-0249, SDC-TRAP-0250, SDC-TRAP-0251, and SDC-TRAP-0252.
Dependencies are inferred from the claim text.